CD8+ tumor-infiltrating lymphocytes are primed for fas-mediated activation-induced cell death but are not apoptotic in situ

Journal of Immunology

Volumn 166, Issue 10, 2001, Pages 6074-6083

  Radoja, Sasa ^a,b   Saio, Masanao ^a,c   Frey, Alan B ^a,d  

^a Kaplan Cancer Center   (United States)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD69 ANTIGEN; FAS ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1;

ANIMAL CELL; ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; CELL CYCLE S PHASE; CELL DEATH; CELL KILLING; CELL PROLIFERATION; CYTOKINE RELEASE; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; LIGAND BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE;

EID: 0035873472     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.166.10.6074     Document Type: Article

References (40)

1. Refaeli, Y., L. Van Parijs, C. A. London, J. Tschopp, and A. K. Abbas. 1998. Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity. 8:615.
2. McCormack, J. E., J. E. Callahan, J. Kappler, P. C. and Marrack. 1993. Profound deletion of mature T cells in vivo by chronic exposure to exogenous superantigen. J. Immunol. 150:3785.
3. Chen, Y., J. Inobe, R. Marks, P. Gonnella, V. K. Kuchroo, and H. L. Weiner. 1995. Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature 376:177.
4. Moskophidis, D., F. Leehner, H. Pircher, and R. M. Zinkernagel. 1993. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 162:758.
5. Suzuki, G., Y. Kawase, S. Koyasu, I. Yahara, Y. Kobayashi, and R. H. Schwartz, 1988. Antigen-induced suppression of the proliferative response of T cell clones. J. Immunol. 1-10:1359.
6. Alexander-Miller, M. A., G. R. Leggatt, A. Sarin, and J. A. Berzofsky. 1996. Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL. J. Exp. Med. 184:485.
7. Evans, R., S. J. Kamdar, T. M. Duffy, D. M. Krupke, J. A. Fuller, and M. E. Dudley. 1995. The therapeutic efficacy of murine anti-tumor T cells: freshly isolated T cells are more therapeutic than T cells expanded in vitro. Anticancer Res. 15:441.
8. Rosenberg, S. A. 1998. New opportunities for the development of cancer immunotherapies. Cancer J. Sci. Am. 4(Suppl. 1):S1.
9. Finke, J., S. Ferrone, A. Frey, A. Mufson, and A. Ochoa. 1999. Where have all the T cells gone: mechanisms of immune evasion by tumors. Immunol. Today 20:158.
10. Bennett, M. W., J. O'Connell, G. C. O'Sullivan, C. Brady, D. Roche, J. K. Collins, and F. Shanahan. 1998. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J. Immunol. 160:5669.
11. Hahne, M., D. Rimoldi, M. Schroter, P. Romero, M. Schreier, L. E. French, P. Schneider, T. Bornand, A. Fontana, D. Lienard, J. Cerottini, and J. Tschopp. 1996. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science 274:1363.
12. O'Connell, J., G. C. O'Sullivan, J. K. Collins, and F. Shanahan. 1996. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 184:1075.
13. Rabinowich, H., T. E. Reichert, Y. Kashii, B. R. Gastman, M. C. Bell, and T. L. Whiteside. 1998. Lymphocyte apoptosis induced by Fas ligund-expressing ovarian carcinoma cells: implications for altered expression of T cell receptor in tumor-associated lymphocytes. J. Clin. Invest. 101:2579.
14. Saas, P., P. R. Walker, M. Hahne, A. L. Quiquerez, V. Schnuriger, G. Perrin, L. French, E. G. Van Meir, N. de Tribolet, J. Tschopp, and P. Y. Dietrich. 1997. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J. Clin. Invest. 99:1173.
15. Shiraki, K., N. Tsuji, T. Shioda, K. J. Isselbacher, and H. Takahashi. 1997. Expression of Fas ligand in liver metastases of human colonie adenocarcinomas Proc. Natl. Acad. Sci. USA 94:6420.
16. Strand, S., W. J. Hofmann, H. Hug, M. Muller, G. Otto, D. Strand, S. M. Mariani, W. Stremmel, P H. Krammer, and P. R. Galle. 1996. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion? Nat. Med. 2:1361.
17. Uzzo, R. G., P. Rayman, V. Kolenko, P. E. Clark, T. Bloom, A. M. Ward, L. Molto, C. Tannenbaum, L. J. Worford, R. Bukowski, et al. 1999. Mechanisms of apoptosis in T cells from patients with renal cell carcinoma. Clin. Cancer Res. 5:1219.
18. Walker, P. R., P. Saas, and P. Y. Dietrich. 1997. Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. J. Immunol. 158:4521.
19. Chappell, D. B., T. Z. Zaks, S. A. Rosenberg, and N. P. Restifo. 1999. Human melanoma cells do not express Fas (Apo-1/CD95) ligand. Cancer Res. 59:59.
20. O'Connell, J., M. W, Bennett, G. C. O'Sullivan, J. K. Collins, and F. Shanahan. 1999. The Fas counterattack: cancer as a site of immune privilege. Immunol. Today 20:46
21. Appleman, L. J., J. Uyeki, and A. B. Frey. 1995. Mouse embryo fibroblasts transformed by activated ras or dominant-negative p53 express cross-reactive tumor rejection antigens. Int. J. Cancer 61:887.
22. Radoja, S., T. D. Rao, D. Hillman, and A. B. Frey. 2000. Mice bearing late-stage tumors have normal functional systemic T cell responses in vitro and in vivo. J. Immunol. 164:2619.
23. + T cells results in altered cytokine production, activation threshold, and costimulatory requirements. J. Immunol., 163:5937.
24. Tan, M. H., E. D. Holyoke, and M. H. Goldrosen. 1976. Murine colon adenocarcinomas: methods for selective culture in vitro. J. Natl. Cancer Inst. 56:871.
25. Eerola, A. K., Y. Soini, and P. Paakko. 1999. Tumour infiltrating lymphocytes in relation to tumour angiogenesis, apoptosis and prognosis in patients with large cell lung carcinoma. Lung Cancer 26:73.
26. Gastman, B. R., Y. Atarshi, T. E. Reichert, T. Saito, L. Balkir, H. Rabinowich, and T. L. Whiteside. 1999. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res. 59:5356.
27. Munakata, S., T. Enomoto, M. Tsujimoto, Y. Otsuki, H. Miwa, H. Kanno, and K. Aozasa. 2000. Expressions of Fas ligand and other apoptosis-related genes and their prognostic significance in epithelial ovarian neoplasms. Br. J. Cancer 82: 1446.
28. O'Connell, J., M. W. Bennett, G. C. O'Sullivan, J. O'Callaghan, J. K. Collins, and F. Shanahan. 1999. Expression of Fas (CD95/APO-1) ligand by human breast cancers: significance for tumor immune privilege. Clin. Diagn. Lab. Immunol. 6:457.
29. Restifo, N. P. 2000. Not so fas: re-evaluating the mechanisms of immune privilege and tumor escape. Nat. Med. 6:493.
30. Whiteside, T. L. 1998. Immune cells in the tumor microenvironment: mechanisms responsible for functional and signaling defects. Adv. Exp. Med. Biol. 451: 167.
31. Levey, D., and P. Srivastava. 1996. Alterations in T cells of cancer-bearers: whence specificity? Immunol. Today 17:365.
32. Gastman, B. R., D. E. Johnson, T. L. Whiteside, and H. Rabinowich. 2000. Tumor-induced apoptosis of T lymphocytes: elucidation of intracellular apoptotic events. Blood 95:2015.
33. Prevost-Blondel, A., C. Zimmermann, C. Stemmer, P. Kulmburg, F. M. Rosenthal, and H. Pircher. 1998. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. J. Immunol. 161:2187.
34. Maeda, K., R. Lafreniere, and L. M. Jerry. 1991. Production and characterization of tumor infiltrating lymphocyte clones derived from B16-F10 murine melanoma. J. Invest. Dermatol. 97:183.
35. Topalian, S. L., L. M. Muul, D. Solomon, and S. A. Rosenberg. 1987. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J. Immunol. Methods 102:127.
36. Plautz, G. E., J. E. Touhalisky, and S. Shu. 1997. Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cells. Cell. Immunol. 178:101.
37. Bachmann, M. F., M. Barner, A. Viola, and M. Kopf. 1999. Distinct kinetics of cytokine production and cytolysis in effector and memory T cells after viral infection. Eur. J. Immunol. 29:291.
38. Zimmermann, C., A. Prevost-Blondel, C. Blaser, and H. Pircher. 1999. Kinetics of the response of naive and memory CD8 T cells to antigen: similarities and differences. Eur. J. Immunol. 29:284.
39. Lopez, C., T. D. Rao, H. Feiner, R. Shapiro, J. Marks, and A. B. Frey. 1998. Repression of interleukin-2 mRNA translation in primary human breast carcinoma tumor infiltrating lymphocytes. Cell. Immunol. 190:141.
40. Frey, A. B., and T. D. Rao. 1999. NKT cell cytokine imbalance in murine diabetes mellitus. Autoimmunity 29:201.